Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-3880 versus EU Aranesp bioequivalence PK/PD crossover study in healthy volunteers
NL-OMON41044Phase 1Active, not recruiting
- Sponsor
- Dong-A ST
- Start
- Jul 2014
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA-3880 and darbepoetin alfa in anaemia (4 arms), sponsored by Dong-A ST. Primary endpoints: Bioequivalence after single intravenous administration and Bioequivalence after single subcutaneous administration. Started Jul 2014; status: active, not recruiting.
02
Drugs
DA-3880darbepoetin alfa
03
Conditions
anaemia
Beyond the preview
Go deeper on NL-OMON41044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41044.